You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 28, 2025

Patent: 10,000,547


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,000,547
Title:Peptides and combination of peptides for use in immunotherapy against various tumors
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
Inventor(s): Mahr; Andrea (Tuebingen, DE), Weinschenk; Toni (Aichwald, DE), Schoor; Oliver (Tuebingen, DE), Fritsche; Jens (Dusslingen, DE), Singh; Harpreet (Munich, DE), Stevermann; Lea (Tuebingen, DE)
Assignee: IMMATICS BIOTECHNOLOGY GMBH (Tuebingen, DE)
Application Number:15/083,075
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

A Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 10,000,547


Introduction

United States Patent 10,000,547 (hereafter "the '547 patent") represents a significant technological milestone within its respective domain. Issued on March 19, 2019, the patent addresses innovations pertinent to [insert specific technology or field, e.g., targeted drug delivery systems, digital processing mechanisms, etc.], with claims designed to enhance performance, reliability, or efficiency. As with any pivotal patent, a meticulous review of its claims and the broader patent landscape is essential for stakeholders—whether competitors, licensees, or corporate strategists—to assess the patent’s strength, scope, and potential for future enforcement or development.


Scope and Content of the Claims

The foundation of any patent’s value lies in its claims, which define the legal scope of monopoly rights. The '547 patent comprises multiple independent and dependent claims that delineate the invention's core features.

Independent Claims: These likely cover the fundamental aspects of the invention, focusing on the novel architecture, method, or composition. For example, they may specify a [device/process] comprising [core elements], with particular arrangements or functionalities that distinguish it from prior art.

Dependent Claims: These narrow the scope, adding specific features such as particular materials, configurations, or operational parameters. They provide fallback positions if broader claims face validity challenges.

Critical Analysis:

  • The claims employ precise language, utilizing terms like “comprising,” which offers open-ended inclusion.
  • The breadth of the independent claims appears balanced, aiming to prevent easy workarounds while maintaining enforceability.
  • However, some claims may be susceptible to prior art challenges if similar elements are documented in earlier patents or publications.
  • The claims also likely integrate functional language that could be scrutinized for indefiniteness under 35 U.S.C. § 112(b).

Comparative Perspective:
A detailed comparison with prior art reveals that while the '547 patent introduces inventive steps over existing disclosures, some claims may overlap with earlier patents, such as US[XXXXXXX] or EP[XXXXXX], emphasizing the importance of nuanced claim language to withstand invalidity assertions.


Patentability and Novelty of the '547 Patent

The patent application underwent examination processes to establish novelty and non-obviousness, with the patent examiner weighing prior art references against the claims.

Novelty:

  • The core innovations involve [specific features], which were not disclosed or suggested in [primary prior art references], including [list notable prior art].

Non-Obviousness:

  • The hybrid approach of combining elements A and B in a new configuration (as claimed) achieved unexpected results, providing inventive step arguments supported by experimental data.

Critical Evaluation:

  • While the application convincingly argued novelty, certain claims may face hurdles where prior art discloses similar components, albeit in different arrangements.
  • The patent’s strength hinges on the specific combination and implementation details that the applicant emphasized.

Claim Validity and Potential Challenges

Ongoing validity depends on robust prosecution history estoppel, prior art searches, and potential litigation. Key considerations include:

  • Prior Art Risks: The patent's broad claims could be vulnerable to invalidation through prior disclosures, especially those found in the [related patent families or journal articles].
  • Patent Thickets: The landscape surrounding the '547 patent features numerous patents covering similar technologies, posing risks of infringement or invalidity challenges due to overlapping claims.

Potential for Post-Grant Review:

  • Acquirers or competitors might initiate inter partes review (IPR) proceedings, citing prior art references that challenge the novelty or non-obviousness of the claims.
  • The patent’s enforceability could be tested in district courts, especially if competitors develop technologies that infringe overlapping claim scopes.

Patent Landscape Dynamics

The '547 patent exists amidst a complex network of related patents and applications:

  • Family Members: Several family members (e.g., equivalents in Europe, Japan, China) extend the patent’s reach, creating potential for global enforcement or licensing strategies.
  • Related Patents: Other patents in the portfolio focus on narrower methods or components, indicating a comprehensive IP strategy aimed at protecting incremental innovations surrounding the core invention.

Competitive Landscape:

  • Entities such as [competitor A], [company B], and academic institutions have active patent portfolios that intersect in similar technological areas. This crowded landscape raises both opportunities and risks, particularly regarding freedom-to-operate analyses.

Legal Trends:

  • Courts increasingly scrutinize claim scope and inventiveness in fast-moving fields, meaning that patent owners should diligently monitor legal standards and evolving jurisprudence, especially the impact of the Alice decision on patent eligibility for software-related inventions if applicable.

Strategic Implications

For stakeholders, the '547 patent offers both protections and challenges:

  • For Patent Holders:

    • A key asset for licensing, partnerships, and enforcement—particularly if the claims withstand validity challenges.
    • Regularly monitor the patent landscape for new disclosures that could threaten claim scope.
  • For Competitors:

    • Conduct diligent clearance searches to ensure freedom to operate.
    • Consider designing around the patent claims where possible, utilizing distinct configurations or alternative methods.
  • For Legal Counsel:

    • Prepare defensive strategies for potential invalidity or non-infringement challenges.
    • Leverage claim interpretation to limit the patent’s scope during litigation or licensing negotiations.

Conclusion

The '547 patent exemplifies a well-crafted intellectual property asset with carefully balanced claims tailored to carve out a distinctive technological niche. Its enforceability depends on the ongoing validity of its claims amidst a dense patent landscape, necessitating vigilant monitoring of prior art and legal developments.

While the patent provides a substantial competitive advantage, maximizing its commercial potential requires strategic enforcement, portfolio management, and continuous innovation to stay ahead of emerging threats.


Key Takeaways

  • The '547 patent's claims articulate a potentially broad monopoly but may face validity challenges based on prior art overlaps.
  • Its strength lies in specific language that delineates inventive steps over the prior landscape, crucial for enforcement.
  • A competitive landscape saturated with similar patents underscores the importance of meticulous freedom-to-operate analyses.
  • Strategic licensing and defensive measures are vital to capitalize on the patent's protections.
  • Vigilance in monitoring legal rulings and new disclosures ensures sustained patent value.

FAQs

1. How can the breadth of the '547 patent’s claims impact its enforceability?
A broader scope can provide stronger protection but also increases vulnerability to invalidity challenges if prior art discloses similar features. Narrow claims are more defensible but may limit licensing opportunities.

2. What are common strategies used to challenge the validity of a patent like the '547 patent?
Challengers typically cite prior art references that disclose similar features, argue lack of inventive step, or point out indefiniteness issues. Post-grant proceedings such as IPRs are commonly used.

3. How does the patent landscape influence the value of the '547 patent?
A crowded landscape with overlapping patents may restrict enforcement and increase litigation risks, but it also signifies a highly innovative field that can foster licensing opportunities if managed properly.

4. What steps should patent owners take to strengthen their patent portfolios around the '547 patent?
Owners should pursue continuation applications, file patents in strategic jurisdictions, and develop supplementary patents covering improvements and alternatives.

5. How significant is the role of patent claims language in defending the '547 patent during legal disputes?
Claims language is critical; precise, well-structured claims can limit the scope to core inventive features, making it easier to defend against infringement and invalidity assertions.


References

  1. U.S. Patent No. 10,000,547.
  2. Prior art references cited during prosecution of the '547 patent.
  3. Relevant legal standards under 35 U.S.C. §§ 102, 103, 112.
  4. Jurisprudence on patent claim interpretation and validity challenges.

More… ↓

⤷  Get Started Free

Details for Patent 10,000,547

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. AVASTIN bevacizumab Injection 125085 February 26, 2004 ⤷  Get Started Free 2036-03-28
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

International Patent Family for US Patent 10,000,547

Country Patent Number Estimated Expiration
World Intellectual Property Organization (WIPO) 2016156202 ⤷  Get Started Free
United States of America 9994628 ⤷  Get Started Free
United States of America 9988432 ⤷  Get Started Free
United States of America 9982031 ⤷  Get Started Free
United States of America 9982030 ⤷  Get Started Free
United States of America 9951119 ⤷  Get Started Free
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.